Literature DB >> 32535624

Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors.

Wadi Mawad1,2, Luc Mertens1, Joseph J Pagano3, Eugenie Riesenkampff1, Marjolein J E Reichert1, Seema Mital1, Paul F Kantor4, Mark Greenberg1, Peter Liu5, Paul C Nathan1, Lars Grosse-Wortmann1,6.   

Abstract

AIMS: Anthracyclines are a cornerstone of paediatric cancer treatment. We aimed to quantify myocardial cardiac magnetic resonance (CMR) native T1 (NT1) and extracellular volume fraction (ECV) as markers of fibrosis in a cohort of childhood cancer survivors (CCS). METHODS AND
RESULTS: A cohort of CCS in remission underwent CMR T1 mapping. Diastolic function was assessed by echocardiography. Results were compared to a cohort of normal controls of similar age and gender. Fifty-five CCS and 46 controls were included. Both groups had similar mean left ventricular (LV) NT1 values (999 ± 36 vs. 1007 ± 32 ms, P = 0.27); ECV was higher (25.6 ± 6.9 vs. 20.7 ± 2.4%, P = 0.003) and intracellular mass was lower (37.5 ± 8.4 vs. 43.3 ± 9.9g/m2, P = 0.02) in CCS. The CCS group had lower LV ejection fraction (EF) and LV mass index with otherwise normal diastolic function in all but one patient. The proportion of subjects with elevated ECV compared to controls did not differ between subgroups with normal or reduced LV EF (22% vs. 28%; P = 0.13) and no correlations were found between LVEF and ECV. While average values remained within normal range, mitral E/E' (6.6 ± 1.6 vs. 5.9 ± 0.9, P = 0.02) was higher in CCS. Neither NT1 nor ECV correlated with diastolic function indices or cumulative anthracycline dose.
CONCLUSIONS: There is evidence for mild diffuse extracellular volume expansion in some asymptomatic CCS; myocyte loss could be part of the mechanism, accompanied by subtle changes in systolic and diastolic function. These findings suggest mild myocardial damage and remodelling after anthracycline treatment in some CCS which requires continued monitoring. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  T1 mapping; anthracycline cardiotoxicity; cardiac function; cardiovascular magnetic resonance; myocardial fibrosis

Mesh:

Substances:

Year:  2021        PMID: 32535624      PMCID: PMC7984732          DOI: 10.1093/ehjci/jeaa093

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  35 in total

Review 1.  Delayed Myocardial Enhancement in Cardiac Magnetic Resonance Imaging.

Authors:  Arie Franco; Saeed Javidi; Stefan G Ruehm
Journal:  J Radiol Case Rep       Date:  2015-06-30

Review 2.  Myocardial Protection During Cardiotoxic Chemotherapy.

Authors:  Ronald M Witteles; Xavier Bosch
Journal:  Circulation       Date:  2015-11-10       Impact factor: 29.690

Review 3.  The continuing challenge of evaluating diastolic function by echocardiography in children: developing concepts and newer modalities.

Authors:  Wadi Mawad; Mark K Friedberg
Journal:  Curr Opin Cardiol       Date:  2017-01       Impact factor: 2.161

4.  Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging.

Authors:  Gregory T Armstrong; Juan Carlos Plana; Nan Zhang; Deokumar Srivastava; Daniel M Green; Kirsten K Ness; F Daniel Donovan; Monika L Metzger; Alejandro Arevalo; Jean-Bernard Durand; Vijaya Joshi; Melissa M Hudson; Leslie L Robison; Scott D Flamm
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

5.  Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.

Authors:  Steven E Lipshultz; David C Landy; Gabriela Lopez-Mitnik; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Carol A French; Amy M Rovitelli; Cindy Proukou; M Jacob Adams; Tracie L Miller
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

6.  Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.

Authors:  Olga H Toro-Salazar; Eileen Gillan; Michael T O'Loughlin; Georgine S Burke; Joanna Ferranti; Jeffrey Stainsby; Bruce Liang; Wojciech Mazur; Subha V Raman; Kan N Hor
Journal:  Circ Cardiovasc Imaging       Date:  2013-10-04       Impact factor: 7.792

7.  Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.

Authors:  Tomas G Neilan; Otavio R Coelho-Filho; Ravi V Shah; Jiazuo H Feng; Diego Pena-Herrera; Damien Mandry; Francois Pierre-Mongeon; Bobak Heydari; Sanjeev A Francis; Javid Moslehi; Raymond Y Kwong; Michael Jerosch-Herold
Journal:  Am J Cardiol       Date:  2012-12-08       Impact factor: 2.778

8.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.

Authors:  M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal:  Am Heart J       Date:  1981-10       Impact factor: 4.749

Review 9.  Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group.

Authors:  Sadhna M Shankar; Neyssa Marina; Melissa M Hudson; David C Hodgson; M Jacob Adams; Wendy Landier; Smita Bhatia; Kathleen Meeske; Ming Hui Chen; Karen E Kinahan; Julia Steinberger; David Rosenthal
Journal:  Pediatrics       Date:  2008-01-10       Impact factor: 7.124

10.  Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.

Authors:  Daniel A Mulrooney; Mark W Yeazel; Toana Kawashima; Ann C Mertens; Pauline Mitby; Marilyn Stovall; Sarah S Donaldson; Daniel M Green; Charles A Sklar; Leslie L Robison; Wendy M Leisenring
Journal:  BMJ       Date:  2009-12-08
View more
  5 in total

1.  Developing a biomechanical model-based elasticity imaging method for assessing hormone receptor positive breast cancer treatment-related myocardial stiffness changes.

Authors:  Caroline E Miller; Jennifer H Jordan; Alexandra Thomas; Jared A Weis
Journal:  J Med Imaging (Bellingham)       Date:  2021-09-30

2.  Doxorubicin Paradoxically Ameliorates Tumor-Induced Inflammation in Young Mice.

Authors:  Ibrahim Y Abdelgawad; Marianne K O Grant; Flavia E Popescu; David A Largaespada; Beshay N Zordoky
Journal:  Int J Mol Sci       Date:  2021-08-21       Impact factor: 5.923

3.  Divergent Cardiac Effects of Angiotensin II and Isoproterenol Following Juvenile Exposure to Doxorubicin.

Authors:  Kevin Agostinucci; Marianne K O Grant; Davis Seelig; Doğacan Yücel; Jop van Berlo; Alessandro Bartolomucci; Jason R B Dyck; Beshay N Zordoky
Journal:  Front Cardiovasc Med       Date:  2022-03-25

4.  Assessment of late cardiotoxic effects in patients treated for cancer in childhood.

Authors:  Vladimír Kincl; Roman Panovský; Tomáš Kepák; Viera Bajčiová; Veronika Bednárová; Lukáš Opatřil; Jan Máchal
Journal:  Cancer Med       Date:  2022-02-15       Impact factor: 4.711

5.  Appropriate use criteria for cardiovascular magnetic resonance imaging (CMR): SIC-SIRM position paper part 1 (ischemic and congenital heart diseases, cardio-oncology, cardiac masses and heart transplant).

Authors:  Gianluca Pontone; Ernesto Di Cesare; Silvia Castelletti; Francesco De Cobelli; Manuel De Lazzari; Antonio Esposito; Marta Focardi; Paolo Di Renzi; Ciro Indolfi; Chiara Lanzillo; Luigi Lovato; Viviana Maestrini; Giuseppe Mercuro; Luigi Natale; Cesare Mantini; Aldo Polizzi; Mark Rabbat; Francesco Secchi; Aurelio Secinaro; Giovanni Donato Aquaro; Andrea Barison; Marco Francone
Journal:  Radiol Med       Date:  2021-02-24       Impact factor: 3.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.